Rufutalkib
Rufutalkib is an orally active ALK modulator. It possesses thermodynamic and chemical stability, and can be used in research related to anaplastic large cell lymphoma, non-Hodgkin's lymphoma, inflammatory myofibroblastic tumor, neuroblastoma, glioblastoma, and ALK-positive malignancies.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1609170-61-7
- Fòrmula: C29H36ClN5O3S
- Peso molecular:570.15
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
In Vitro
Rufutalkib succinate Form VI has high solubility in simulated gastric fluid (7.34-7.35 mg/mL) and low solubility in fasted-state simulated intestinal fluid (0.10 mg/mL) over a 4-hour period at 37°C[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 1609170-61-7
-
Peso molecular 570.15
-
Fòrmula C29H36ClN5O3S
-
SMILES
CC1=CC(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(C(C)C)(=O)=O)=N2)=C4C(C[C@H](O4)C)=C1C5CCN(CC5)C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Rufutalkib
- 1609170-61-7
- Anaplastic lymphoma kinase (ALK)
- Anaplastic lymphoma kinase
- ALK tyrosine kinase receptor
- CD246
- Cluster of differentiation 246
- anaplastic large cell lymphoma
- ALK
- inflammatory myofibroblastic tumor
- simulated gastric fluid
- fasted-state simulated intestinal fluid
- ALK-positive malignancies
- glioblastoma
- non-Hodgkin lymphoma
- rats
- neuroblastoma
- Inhibitor
- inhibitor
- inhibit